Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Elranatamab Exposure-Efficacy Analysis in Patients with Relapsed or Refractory Multiple Myeloma: Insights from Pooled Magnetismm Studies

Hoi Kei Lon, Jennifer Hibma, Jason Williams, Diane Wang, David Gifondorwa, Wei An Ma, Lindsay King, Umberto Conte, Akos Czibere, Mohamed Elmeliegy

Blood (2023) 142 (Supplement 1): 1995.

https://doi.org/10.1182/blood-2023-190102

Published: 2023

Journal Articles

Soluble B-Cell Maturation Antigen As a Disease Biomarker in Relapsed or Refractory Multiple Myeloma (RRMM): Evaluation from Elranatamab (ELRA) Magnetismm Studies

Mohamed Elmeliegy, Hoi Kei Lon, Diane Wang, Wei An Ma, Lindsay King, Andrea Viqueira, Akos Czibere

Blood (2023) 142 (Supplement 1): 3345.

https://doi.org/10.1182/blood-2023-190341

Published: 2023

Journal Articles

A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Patients with Relapsed and/or Refractory Multiple Myeloma

Sheena Sharma, Diane Wang, Hoi-Kei Lon, Pooneh Soltantabar, Andrea Viqueira, Akos Czibere, Anne Hickman, Jane Liang White, Mohamed Elmeliegy

Blood (2022) 140 (Supplement 1): 10036–10038.

https://doi.org/10.1182/blood-2022-169836

Published: 2022

Journal Articles

Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma

Mohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, Anne Hickman, Jennifer Hibma, Hoi-Kei Lon, Joseph Piscitelli, Pooneh Soltantabar, Diane Wang, Sibo Jiang, Gregory Finn, Akos Czibere

Blood (2022) 140 (Supplement 1): 7174–7175.

https://doi.org/10.1182/blood-2022-169971

Published: 2022